Onconano Medicine, Inc.

Southlake, TX · Founded 2014 · Medtech · Still private

Pegsitacianine (ONM-100), an intravenous pH-sensitive fluorescent imaging agent for real-time intraoperative tumor visualization

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · onconano.com

Sector: Medtech
Headquarters: Southlake, TX
Founded: 2014
Latest Form D: $10.1M, Oct 2026
Total capital: $59.7M

Federal grants: $3.8M; 6 awards · 2017–2023; Rank in peer group#20 of 41
Private capital raised: $55.9M; 4 Form D · last Oct 2026; 1 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 1; 14 pending · first 2024; Rank in peer group#13 of 41

Capital timeline

Latest events

Oct 2026Private capital raisedForm D · SEC · 4th filing$10.1M
Jun 2025Private capital raisedForm D · SEC · 3rd filing$12.7M
Sep 2023Federal grantHealth and Human S · Phase II · Image-guided Surgical Detection of Metastatic Disease to the Peritoneum$2M
Oct 2020Private capital raisedForm D · SEC · 2nd filing$21.5M
Sep 2020Federal grantHealth and Human S · Phase II · Novel Fluorescent Diagnostic Agents for Detection, Staging, andIntraoperative Imaging of Tumors$790
Sep 2019Federal grantHealth and Human S · Phase II · Novel Fluorescent Diagnostic Agents for Detection, Staging, andIntraoperative Imaging of Tumors$837K
Aug 2019Federal grantHealth and Human S · Phase II · Novel Fluorescent Diagnostic Agents for Detection, Staging, andIntraoperative Imaging of Tumors$4K
Mar 2018Private capital raisedForm D · SEC · 1st filing$11.7M

Show 2 earlier federal awards

Sep 2018Federal grantHealth and Human S · Phase II · Novel Fluorescent Diagnostic Agents for Detection, Staging, andIntraoperative Imaging of Tumors$710K
Sep 2017Federal grantHealth and Human S · Phase II · Novel Fluorescent Diagnostic Agents for Detection, Staging, andIntraoperative Imaging of Tumors$269K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

6months

from Onconano Medicine, Inc.’s first federal award to its first private round.

First federal award · Sep 2017: Health and Human S · $269K
First Form D · Mar 2018: $11.7M · 1st Form D
Awards before first raise: 1 award

An association in public records, not a cause or a prediction.

Standing among 41 peers

Line = median

Medtech · Molecule

Federal grants#20 · top 49%
Granted patents#13 · top 32%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Kartik KrishnanResearcherExecutive Officer, DirectorLinked by $2M in grants as PI
Ravi SrinivasanResearcherExecutive Officer, DirectorLinked by $1.8M in grants as PI
Alvaro GuillemExecutive Officer, DirectorNamed in SEC Form D filings
Brett GiroirDirectorNamed in SEC Form D filings
Caleb SmithDirectorNamed in SEC Form D filings
Gina JonesDirectorNamed in SEC Form D filings

Show all 15 people

Jeff KeyserExecutive OfficerNamed in SEC Form D filings
John DyettDirectorNamed in SEC Form D filings
Joydeep GoswamiDirectorNamed in SEC Form D filings
Martin DriscollExecutive Officer, DirectorNamed in SEC Form D filings
Matthew HeadExecutive OfficerNamed in SEC Form D filings
Melissa PaoloniExecutive OfficerNamed in SEC Form D filings
Paritosh DhawaleDirectorNamed in SEC Form D filings
Yumin QiuDirectorNamed in SEC Form D filings
Yumin QuiDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 15

Apr 17, 2025PendingTherapeutic Ph Responsive CompositionsUSPTOApplication 18907886
Nov 12, 2024GrantedTherapeutic Ph Responsive CompositionsUSPTOUS 12,138,344
May 23, 2024PendingPROTONATED pH RESPONSIVE POLYMER ENCAPSULATION OF BISPECIFIC ANTIBODIES AND CYTOKINESUSPTOApplication 18502783

Show all 15 patent records

Therapeutic Ph Responsive CompositionsApr 17, 2025 · Application 18907886Pending
Therapeutic Ph Responsive CompositionsNov 12, 2024 · US 12,138,344Granted
PROTONATED pH RESPONSIVE POLYMER ENCAPSULATION OF BISPECIFIC ANTIBODIES AND CYTOKINESMay 23, 2024 · Application 18502783Pending
Ph Responsive Compositions, Formulations, And Methods Of Imaging A TumorJan 26, 2023 · Application 17756190Pending
pH Responsive Block Copolymers Compositions, Micelles, and Methods of UseDec 29, 2022 · Application 17755671Pending
Ph Responsive Compositions, Formulations, And Methods Of Imaging A TumorApplication PCTUS2020060910Pending
Therapeutic Ph Responsive CompositionsApplication 63109220Pending
Ph Responsive Block Copolymer Compositions, Micelles, And Methods Of UseApplication PCTUS2020058752Pending
pH RESPONSIVE COMPOSITIONS, FORMULATIONS, AND METHODS OF IMAGING A TUMORApplication 62937141Pending
Methods Of Treating Cancer With Polyvalent Sting Activating Compositions And PD-1 InhibitorsApplication PCTUS2025044291Pending
pH RESPONSIVE BLOCK COPOLYMER COMPOSITIONS, MICELLES, AND METHODS OF USEApplication 62930530Pending
Protonated Ph Responsive Polymer Encapsulation Of Bispecific Antibodies And CytokinesApplication PCTUS2023078839Pending
PROTONATED pH RESPONSIVE POLYMER ENCAPSUALTION OF BISPECIFIC ANTIBODIES AND CYTOKINESApplication 63459351Pending
PROTONATED pH RESPONSIVE POLYMER ENCAPSUALTION OF BISPECIFIC ANTIBODIES AND CYTOKINESApplication 63382528Pending
Therapeutic Ph Responsive CompositionsApplication PCTUS2021072215Pending

Tetra Discovery Partners, Inc.Similar federal contract value in Medtech · null in contracts
Combinati IncorporatedSimilar federal contract value in Medtech · null in contracts
Corfigo, Inc.Similar federal contract value in Medtech · null in contracts
AdvancedCPR Solutions LLCSimilar federal contract value in Medtech · null in contracts
GLYSENS, INC.Similar federal contract value in Medtech · null in contracts
AKOYA BIOSCIENCES, INC.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.